Li Yuan, Wang Hanlin L
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, United States.
Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
World J Gastrointest Oncol. 2022 Aug 15;14(8):1375-1387. doi: 10.4251/wjgo.v14.i8.1375.
Published in 2015, the International Consensus Recommendations on Surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients (SCENIC) recommended abandoning the use of diagnostic term "dysplasia-associated lesion or mass (DALM)" for polypoid dysplastic lesions detected in patients with inflammatory bowel disease (IBD). The aim of this study was to investigate whether this recommendation had any influence on diagnostic terminologies used by pathologists in their practice.
We retrospectively reviewed all pathology reports for surveillance colonoscopic biopsies from ulcerative colitis (UC) patients in our institution during 1/2012-12/2014 (pre-SCENIC) and 1/2016-12/2018 (post-SCENIC). These included 1203 biopsies from 901 UC patients during the pre-SCENIC period and 1273 biopsies from 977 UC patients during the post-SCENIC period. Their corresponding endoscopic findings and histopathologic diagnoses were recorded. Clinical indications for total colectomy for UC patients and corresponding histopathologic findings in colectomy specimens were also recorded and compared.
A total of 347 and 419 polyps/polypoid lesions were identified during the pre-SCENIC and post-SCENIC periods, among which 60 and 104 were dysplastic/adenomatous, respectively. More polypoid dysplastic lesions were simply diagnosed as "adenoma" during the post-SCENIC period in comparison with the pre-SCENIC period (97.1% 65.0%; 0.001). The number of cases with a comment in pathology reports regarding the distinction between DALM and sporadic adenoma was also significantly decreased during the post-SCENIC period (5.8% 38.3%; < 0.001). In addition, the term "dysplasia" was more consistently used for random biopsies during the post-SCENIC period. Furthermore, the terms "sessile serrated adenoma/polyp" (SSA/P) and "serrated epithelial change" (SEC) were more consistently used for polypoid lesions and random biopsies, respectively, during the post-SCENIC period, although these were not specifically addressed in the SCENIC recommendations. The indications for colectomy remained unchanged, however, despite the standardization of diagnostic terminologies.
The SCENIC recommendations relieve pathologists from the burden of distinguishing DALM from sporadic adenoma in IBD patients, which helps the standardization of diagnostic terminologies used by pathologists. The consistent use of the diagnostic terminologies may help reduce potential confusions to clinicians and patients.
2015年发布的《炎症性肠病患者大肠内镜下肿瘤检测与管理的国际共识建议》(SCENIC)建议,放弃对炎症性肠病(IBD)患者中检测到的息肉样发育异常病变使用诊断术语“发育异常相关病变或肿块(DALM)”。本研究的目的是调查该建议是否对病理学家在实践中使用的诊断术语有任何影响。
我们回顾性分析了2012年1月至2014年12月(SCENIC之前)以及2016年1月至2018年12月(SCENIC之后)我院溃疡性结肠炎(UC)患者监测性结肠镜活检的所有病理报告。其中包括SCENIC之前901例UC患者的1203份活检以及SCENIC之后977例UC患者的1273份活检。记录了它们相应的内镜检查结果和组织病理学诊断。还记录并比较了UC患者全结肠切除术的临床指征以及结肠切除标本中的相应组织病理学发现。
在SCENIC之前和之后的时期分别鉴定出347个和419个息肉/息肉样病变,其中分别有60个和104个为发育异常/腺瘤性病变。与SCENIC之前的时期相比,在SCENIC之后的时期更多的息肉样发育异常病变被简单诊断为“腺瘤”(97.1%对65.0%;P<0.001)。在SCENIC之后的时期,病理报告中关于区分DALM和散发性腺瘤的注释病例数也显著减少(5.8%对38.3%;P<0.001)。此外,在SCENIC之后的时期,“发育异常”一词在随机活检中使用得更加一致。此外,在SCENIC之后的时期,“无蒂锯齿状腺瘤/息肉”(SSA/P)和“锯齿状上皮改变”(SEC)分别在息肉样病变和随机活检中使用得更加一致,尽管SCENIC建议中未具体提及这些。尽管诊断术语实现了标准化,但结肠切除术的指征保持不变。
SCENIC建议减轻了病理学家区分IBD患者中DALM与散发性腺瘤的负担,这有助于病理学家使用的诊断术语的标准化。诊断术语的一致使用可能有助于减少对临床医生和患者的潜在困惑。